self‐management of oral anticoagulation vs usual care
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
- RR 0.55 [0.36, 0.84]8 studies · 3058 participantsModerate
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (moderate certainty).
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
Self‐monitoring of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
Self‐monitoring of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
Self‐monitoring of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (moderate certainty).
self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
Indacaterol showed no clear difference in number of participants experiencing at least 1 exacerbation… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in complications compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in implant failure compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in partial graft loss compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.